Servizi Italia Valuation
Is SRI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SRI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SRI (€2.36) is trading below our estimate of fair value (€2.52)
Significantly Below Fair Value: SRI is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SRI?
Key metric: As SRI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is SRI's PE Ratio? | |
|---|---|
| PE Ratio | 14.7x |
| Earnings | €4.66m |
| Market Cap | €69.02m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 2.8x |
| PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does SRI's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.3x | ||
HI Health Italia | 14.2x | n/a | €24.6m |
EUK EuKedos | 26.3x | n/a | €18.9m |
SVS Svas Biosana | 6.9x | 13.0% | €37.0m |
IMD I.M.D. International Medical Devices | 9.8x | 18.6% | €25.6m |
SRI Servizi Italia | 14.7x | 16.9% | €69.0m |
Price-To-Earnings vs Peers: SRI is expensive based on its Price-To-Earnings Ratio (14.7x) compared to the peer average (14.3x).
Price to Earnings Ratio vs Industry
How does SRI's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: SRI is good value based on its Price-To-Earnings Ratio (14.7x) compared to the European Healthcare industry average (18.5x).
Price to Earnings Ratio vs Fair Ratio
What is SRI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 14.7x |
| Fair PE Ratio | 16x |
Price-To-Earnings vs Fair Ratio: SRI is good value based on its Price-To-Earnings Ratio (14.7x) compared to the estimated Fair Price-To-Earnings Ratio (16x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €2.36 | €2.38 +0.6% | 3.2% | €2.45 | €2.30 | n/a | 2 |
| Nov ’25 | €2.37 | €2.38 +0.2% | 3.2% | €2.45 | €2.30 | n/a | 2 |
| Oct ’25 | €2.06 | €2.38 +15.3% | 3.2% | €2.45 | €2.30 | n/a | 2 |
| Sep ’25 | €2.03 | €2.28 +12.1% | 7.7% | €2.45 | €2.10 | n/a | 2 |
| Aug ’25 | €1.88 | €2.28 +21.3% | 7.7% | €2.45 | €2.10 | n/a | 2 |
| Jul ’25 | €1.83 | €2.28 +24.3% | 7.7% | €2.45 | €2.10 | n/a | 2 |
| Jun ’25 | €1.90 | €2.28 +20.1% | 7.7% | €2.45 | €2.10 | n/a | 2 |
| May ’25 | €1.82 | €2.23 +22.6% | 10.1% | €2.45 | €2.00 | n/a | 2 |
| Apr ’25 | €1.72 | €2.23 +29.7% | 10.1% | €2.45 | €2.00 | n/a | 2 |
| Mar ’25 | €1.82 | €2.23 +22.6% | 10.1% | €2.45 | €2.00 | n/a | 2 |
| Feb ’25 | €1.56 | €2.23 +42.6% | 10.1% | €2.45 | €2.00 | n/a | 2 |
| Jan ’25 | €1.68 | €2.08 +23.5% | 18.1% | €2.45 | €1.70 | n/a | 2 |
| Dec ’24 | €1.63 | €2.08 +27.3% | 18.1% | €2.45 | €1.70 | n/a | 2 |
| Nov ’24 | €1.20 | €2.48 +106.3% | 1.0% | €2.50 | €2.45 | €2.37 | 2 |
| Oct ’24 | €1.23 | €2.48 +102.0% | 1.0% | €2.50 | €2.45 | €2.06 | 2 |
| Sep ’24 | €1.28 | €2.48 +94.1% | 1.0% | €2.50 | €2.45 | €2.03 | 2 |
| Aug ’24 | €1.31 | €2.48 +89.7% | 1.0% | €2.50 | €2.45 | €1.88 | 2 |
| Jul ’24 | €1.34 | €2.48 +84.7% | 1.0% | €2.50 | €2.45 | €1.83 | 2 |
| Jun ’24 | €1.33 | €2.48 +86.1% | 1.0% | €2.50 | €2.45 | €1.90 | 2 |
| May ’24 | €1.35 | €2.45 +81.5% | 2.0% | €2.50 | €2.40 | €1.82 | 2 |
| Apr ’24 | €1.26 | €2.45 +94.4% | 2.0% | €2.50 | €2.40 | €1.72 | 2 |
| Mar ’24 | €1.36 | €2.80 +105.9% | 10.7% | €3.10 | €2.50 | €1.82 | 2 |
| Feb ’24 | €1.30 | €2.80 +115.4% | 10.7% | €3.10 | €2.50 | €1.56 | 2 |
| Jan ’24 | €1.19 | €2.80 +136.3% | 10.7% | €3.10 | €2.50 | €1.68 | 2 |
| Dec ’23 | €1.29 | €2.80 +117.9% | 10.7% | €3.10 | €2.50 | €1.63 | 2 |
| Nov ’23 | €1.16 | €2.80 +141.4% | 10.7% | €3.10 | €2.50 | €1.20 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Fresenius Medical Care
€12.2b
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
1FME
€41.39
7D
1.4%
1Y
15.5%
Amplifon
€5.2b
Engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.
AMP
€23.26
7D
-3.1%
1Y
-17.7%
Garofalo Health Care
€517.2m
Operates healthcare clinics in Italy.
GHC
€5.84
7D
2.1%
1Y
30.6%